STOCK TITAN

Braxia Scientific Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company, focused on innovative ketamine treatments for depression, also disclosed the issuance of 200,000 common shares valued at $62,000 to settle payments to an independent medical advisor. Braxia operates clinics across Canada and aims to transform mental health treatment. Forward-looking statements indicate potential risks related to regulatory approvals and treatment efficacy.

Positive
  • Participation in HC Wainwright Annual Global Investment Conference can enhance market visibility.
  • Issuance of shares for settling advisory payments indicates active management of operational expenses.
Negative
  • Risks related to ketamine and psilocybin treatments include unproven health benefits and potential side effects.
  • Dependence on regulatory approvals poses a risk to business operations.

TORONTO, Aug. 17, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its management's participation at the upcoming H.C. Wainwright 23rd Annual Global Investment Conference.

The conference will be held virtually on September 13-15, 2021.

For additional information on the conference, please visit HCW Events.

Share Issuance

The Company also announces that it has issued 200,000 common shares to settle the amount of $62,000 owed to an independent contractor providing medical advisory services to the Company.

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD

"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre
Chairman & CEO

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/braxia-scientific-announces-participation-at-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-2021-301356791.html

SOURCE Braxia Scientific Corp.

FAQ

What is Braxia Scientific's participation in the HC Wainwright conference about?

Braxia Scientific is participating in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What is the significance of the common shares issued by Braxia Scientific?

Braxia Scientific issued 200,000 common shares worth $62,000 to settle payments for medical advisory services.

What risks does Braxia Scientific face with its ketamine treatments?

Braxia Scientific faces risks including unproven efficacy of treatments and regulatory approval challenges, impacting its operations.

Where does Braxia Scientific operate its clinics?

Braxia Scientific operates clinics in Mississauga, Toronto, Ottawa, and Montreal.

What is the stock symbol for Braxia Scientific?

The stock symbols for Braxia Scientific are BRAXF on OTC and BRAX on CSE.

BRAXIA SCIENTIFIC CORP

OTC:BRAXF

BRAXF Rankings

BRAXF Latest News

BRAXF Stock Data

946.17k
268.64M
8.68%
0.02%
Biotechnology
Healthcare
Link
United States of America
Toronto